Study on the Effect of Antiretroviral Therapy Centered on Enovirine on PD-1 Expression of CD8+ T Cells Induced by Cholesterol

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500113428

Enrollment

Unknown

Registered

2025-11-28

Start date

2023-08-04

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Interventions

Experimental group:Switching from efavirenz to enovirine for antiviral therapy

Control group:Use efavirenz

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV-infected individuals (HIV RNA 5.2 mmol/L).

Exclusion criteria

Exclusion criteria: 1. Within 30 days prior to the screening period, there was an occurrence of AIDS-related opportunistic infections or tumors; 2. A known history of previous HIV drug resistance (confirmed HIV viral load > 200 copies/ml) or a history of resistance to any nucleoside (acid) analogue.

Design outcomes

Primary

Measure	Time frame
Blood lipid;Lymphocyte subpopulation;PD-1;	—

Countries

China

Contacts

Public ContactRongrong Zheng

Xixi Hospital of Hangzhou

13438033690@163.com+86 134 3803 3690

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026